The present invention relates to a vaccine formulation against Toxoplasma gondii infection. More specifically, the invention relates to a vaccine formulation in which a Toxoplasma gondii-derived soluble protein is included in liposomes each having an oligosaccharide capable of binding to a carbohydrate recognition molecule on the surface of antigen-presenting cells on the surface of the liposome.
